These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 33053854)

  • 21. The emerging role of α-synuclein truncation in aggregation and disease.
    Sorrentino ZA; Giasson BI
    J Biol Chem; 2020 Jul; 295(30):10224-10244. PubMed ID: 32424039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolvability and Neurodegenerative Disease: Antagonistic Pleiotropy Phenomena Derived from Amyloid Aggregates.
    Hashimoto M; Ho G; Takamatsu Y; Shimizu Y; Sugama S; Takenouchi T; Waragai M; Masliah E
    J Parkinsons Dis; 2018; 8(3):405-408. PubMed ID: 30010144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cross-seeding of alpha-synuclein aggregation by amyloid fibrils of food proteins.
    Vaneyck J; Segers-Nolten I; Broersen K; Claessens MMAE
    J Biol Chem; 2021; 296():100358. PubMed ID: 33539920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Generic inhibition of amyloidogenic proteins by two naphthoquinone-tryptophan hybrid molecules.
    Scherzer-Attali R; Shaltiel-Karyo R; Adalist YH; Segal D; Gazit E
    Proteins; 2012 Aug; 80(8):1962-73. PubMed ID: 22488522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Formation of amyloid fibrils by the regulatory 14-3-3
    Šulskis D; Žiaunys M; Sakalauskas A; Sniečkutė R; Smirnovas V
    Open Biol; 2024 Jan; 14(1):230285. PubMed ID: 38228169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of Helical Intermediates During Amyloid Formation by Intrinsically Disordered Polypeptides and Proteins.
    Abedini A; Cao P; Raleigh DP
    Methods Mol Biol; 2016; 1345():55-66. PubMed ID: 26453205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polyphenol-solubility alters amyloid fibril formation of α-synuclein.
    So M; Kimura Y; Yamaguchi K; Sugiki T; Fujiwara T; Aguirre C; Ikenaka K; Mochizuki H; Kawata Y; Goto Y
    Protein Sci; 2021 Aug; 30(8):1701-1713. PubMed ID: 34046949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interactions of amyloidogenic proteins.
    Giasson BI; Lee VM; Trojanowski JQ
    Neuromolecular Med; 2003; 4(1-2):49-58. PubMed ID: 14528052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elucidating the Role of Lipids in the Aggregation of Amyloidogenic Proteins.
    Kurouski D
    Acc Chem Res; 2023 Nov; 56(21):2898-2906. PubMed ID: 37824095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of amyloidogenic proteins in the microbiomes of a rat Parkinson's disease model and wild-type rats.
    Christensen LFB; Alijanvand SH; Burdukiewicz M; Herbst FA; Kjeldal H; Dueholm MS; Otzen DE
    Protein Sci; 2021 Sep; 30(9):1854-1870. PubMed ID: 34075639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phenolic compounds prevent the oligomerization of α-synuclein and reduce synaptic toxicity.
    Takahashi R; Ono K; Takamura Y; Mizuguchi M; Ikeda T; Nishijo H; Yamada M
    J Neurochem; 2015 Sep; 134(5):943-55. PubMed ID: 26016728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gallic acid oxidation products alter the formation pathway of insulin amyloid fibrils.
    Sakalauskas A; Ziaunys M; Smirnovas V
    Sci Rep; 2020 Sep; 10(1):14466. PubMed ID: 32879381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implications of peptide assemblies in amyloid diseases.
    Ke PC; Sani MA; Ding F; Kakinen A; Javed I; Separovic F; Davis TP; Mezzenga R
    Chem Soc Rev; 2017 Oct; 46(21):6492-6531. PubMed ID: 28702523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. General Aggregation-Induced Emission Probes for Amyloid Inhibitors with Dual Inhibition Capacity against Amyloid β-Protein and α-Synuclein.
    Jia L; Wang W; Yan Y; Hu R; Sang J; Zhao W; Wang Y; Wei W; Cui W; Yang G; Lu F; Zheng J; Liu F
    ACS Appl Mater Interfaces; 2020 Jul; 12(28):31182-31194. PubMed ID: 32584021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Copper and iron ions accelerate the prion-like propagation of α-synuclein: A vicious cycle in Parkinson's disease.
    Li Y; Yang C; Wang S; Yang D; Zhang Y; Xu L; Ma L; Zheng J; Petersen RB; Zheng L; Chen H; Huang K
    Int J Biol Macromol; 2020 Nov; 163():562-573. PubMed ID: 32629061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. N-Terminal Acetylation Affects α-Synuclein Fibril Polymorphism.
    Watson MD; Lee JC
    Biochemistry; 2019 Sep; 58(35):3630-3633. PubMed ID: 31424918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mixed pathologies in pancreatic β cells from subjects with neurodegenerative diseases and their interaction with prion protein.
    Martinez-Valbuena I; Valenti-Azcarate R; Amat-Villegas I; Marcilla I; Marti-Andres G; Caballero MC; Riverol M; Tuñon MT; Fraser PE; Luquin MR
    Acta Neuropathol Commun; 2021 Apr; 9(1):64. PubMed ID: 33832546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spatiotemporal modulations in heterotypic condensates of prion and α-synuclein control phase transitions and amyloid conversion.
    Agarwal A; Arora L; Rai SK; Avni A; Mukhopadhyay S
    Nat Commun; 2022 Mar; 13(1):1154. PubMed ID: 35241680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preparation of Amyloid Fibrils for Magic-Angle Spinning Solid-State NMR Spectroscopy.
    Tuttle MD; Courtney JM; Barclay AM; Rienstra CM
    Methods Mol Biol; 2016; 1345():173-83. PubMed ID: 26453212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alpha-synuclein phosphorylation induces amyloid conversion via enhanced electrostatic bridging: Insights from molecular modeling of the full-length protein.
    Semenyuk PI
    Biophys Chem; 2024 Apr; 307():107196. PubMed ID: 38335809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.